Share This Page
Drug Price Trends for NDC 49884-0465
✉ Email this page to a colleague
Average Pharmacy Cost for 49884-0465
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CHOLESTYRAMINE POWDER | 49884-0465-66 | 0.09032 | GM | 2024-12-18 |
| CHOLESTYRAMINE PACKET | 49884-0465-65 | 0.67982 | EACH | 2024-12-18 |
| CHOLESTYRAMINE PACKET | 49884-0465-64 | 0.67982 | EACH | 2024-12-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 49884-0465
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
49884-0465 Market Analysis and Financial Projection
Market Analysis and Price Projections for Cholestyramine (NDC: 49884-0465)
Overview of Cholestyramine
Cholestyramine, a bile acid sequestrant, is a vital medication used in the management of hypercholesterolemia, pruritus associated with partial biliary obstruction, and diarrhea resulting from bile acid malabsorption. It is available in various formulations, including the oral powder for suspension, which is identified by the NDC code 49884-0465[4].
Market Size and Growth Projections
The global cholestyramine market was valued at USD 186.60 million in 2023 and is projected to reach USD 196.08 million in 2024. The market is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.42%, reaching USD 270.03 million by 2030[1].
Key Market Drivers
Increasing Prevalence of Cardiovascular Diseases
The rising incidence of heart disease and other cholesterol-related conditions significantly drives the demand for effective lipid-lowering treatments like cholestyramine. This trend is expected to continue, fueling market growth[1][4].
Growing Geriatric Population
An aging population is more prone to hyperlipidemia, contributing to the steady demand for cholestyramine. As the global population ages, this segment is anticipated to play a crucial role in market expansion[1][4].
Government Health Initiatives
Public health efforts and government-led initiatives promoting preventive medicine and chronic disease management support market growth. These initiatives often include recommendations for lipid-lowering therapies, which benefit the cholestyramine market[3][4].
Advancements in Drug Formulations
Innovations aimed at enhancing patient compliance and reducing side effects are expected to boost market demand. For instance, the development of powdered or liquid forms of cholestyramine, such as the one identified by NDC 49884-0465, makes the medication easier to ingest, thereby improving patient adherence[1][4].
Competitive Landscape
The cholestyramine market is highly competitive, with key players focusing on strategic partnerships, innovative product developments, and market positioning. The use of Porter's Five Forces framework helps businesses assess the competitive landscape and make informed investment decisions. Companies like Par Pharmaceutical, Inc., and Endo USA, Inc., are significant players in this market[4][5].
Product Development and Innovation
Innovations in cholestyramine formulations are crucial for enhancing patient compliance. The development of powdered forms, such as the one with NDC 49884-0465, is particularly important. Additionally, creating combination therapies and leveraging digital health tools can provide a competitive edge in the market. For example, digital tools can help patients track their medication adherence and monitor their cholesterol levels more effectively[1][4].
Regional Insights
Asia Pacific
Countries like China and India are emerging as significant markets due to the increasing prevalence of lifestyle diseases and improving healthcare infrastructure. These regions offer substantial growth opportunities for the cholestyramine market[3][4].
Middle East and Africa
Variability in access to healthcare services affects the adoption and usage of lipid-lowering agents in these regions. However, public health efforts and private investments are gradually improving the situation, presenting potential growth areas[3].
Price Analysis
The price of cholestyramine powder, as identified by NDC 49884-0465, is relatively stable. As of December 2024, the price per unit is approximately $0.09032 per gram, indicating a consistent pricing strategy across different manufacturers and pharmacies[1].
Price Projections
Given the mid-single-digit percent annual price erosion expected in the generic drug industry, the price of cholestyramine is likely to remain stable or experience minor reductions. However, this erosion is balanced by modest revenue growth, which is an improvement from recent trends[3].
Challenges and Restraints
Alternative Treatments
The availability of alternative lipid-lowering agents, such as statins and other bile acid sequestrants, poses a significant challenge to the cholestyramine market. These alternatives may offer better efficacy or fewer side effects, potentially reducing the demand for cholestyramine[1][4].
Regulatory Hurdles
Regulatory challenges, including potential increases in FDA inspections of foreign manufacturing facilities and price-fixing litigation, can impact the generic drug industry. These hurdles may affect the supply chain and pricing of cholestyramine[3].
Opportunities for Market Expansion
Expanding Therapeutic Applications
There are opportunities in expanding the therapeutic applications of cholestyramine beyond its current uses. Research into new indications could increase the market size and demand for the drug[1][4].
Leveraging Digital Health Tools
Utilizing digital health tools to enhance patient compliance and monitor treatment outcomes can provide a competitive edge. These tools can help in better disease management and improve the overall efficacy of the treatment[1][4].
Emerging Markets
Tapping into emerging markets, particularly in the Asia Pacific region, offers significant growth potential. Improving healthcare infrastructure and increasing awareness of lipid-lowering treatments in these regions can drive market expansion[3][4].
Key Takeaways
- The cholestyramine market is expected to grow at a CAGR of 5.42% from 2023 to 2030.
- Key drivers include the increasing prevalence of cardiovascular diseases and a growing geriatric population.
- Alternative treatments and regulatory hurdles are significant restraints.
- Expanding therapeutic applications and leveraging digital health tools offer promising opportunities.
- Price variability exists based on formulation and pharmacy, with generic versions available.
FAQs
1. What is the primary use of cholestyramine? Cholestyramine is primarily used in the management of hypercholesterolemia, pruritus associated with partial biliary obstruction, and diarrhea resulting from bile acid malabsorption[1][4].
2. What is the expected market size of cholestyramine by 2030? The cholestyramine market is projected to reach USD 270.03 million by 2030, growing at a CAGR of 5.42% from 2023[1].
3. What are the key drivers of the cholestyramine market? Key drivers include the increasing prevalence of cardiovascular diseases, a growing geriatric population, government health initiatives, and advancements in drug formulations[1][4].
4. How does the competitive landscape of the cholestyramine market look? The market is highly competitive, with key players focusing on strategic partnerships, innovative product developments, and market positioning. Companies like Par Pharmaceutical, Inc., and Endo USA, Inc., are significant players[4][5].
5. What opportunities exist for market expansion? Opportunities exist in expanding therapeutic applications, leveraging digital health tools, and tapping into emerging markets, particularly in the Asia Pacific region[1][3][4].
Sources
- 360iResearch: Cholestyramine Market Size & Share 2025-2030[1].
- Drugs.com: Cholestyramine Prices, Coupons, Copay Cards & Patient Assistance[2].
- S&P Global: Pharmaceutical Industry 2024 Credit Outlook Is Stable As Revenue Growth Mitigates Pressures[3].
- DailyMed: CHOLESTYRAMINE powder, for suspension[5].
- FDA Report: NDC 49884-466 Oral Powder, For Suspension Cholestyramine[4].
More… ↓
